Stefan Zimmermann serves as associate head of the Innovative Therapies Unit at the Immuno-oncology service of the University Hospital in Lausanne, Switzerland, a unit dedicated to phase 1 and 2 clinical trials as well as commercial cellular therapies in cancer immunotherapy. His main areas of research and clinical interest are early IO drug development, including T-cell and dendritic cell therapies. Dr Zimmermann is in charge of teaching and patient care and is involved in a portfolio of more than a dozen clinical trials investigating new anticancer agents.
An active member of the Swiss Group for Cancer Research SAKK, he is building partnerships to combine local expertise in translational research with industrial therapeutic innovation. Author of several peer-reviewed manuscripts and book chapters, he serves on the Editorial Board of different clinical cancer journals, and acts as reviewer for multiple cancer immunotherapy publications. He sits on the scientific advisory board of several biotechnology companies.
Dr Zimmermann also serves in the regional Ethics Commission for human research, and participates as faculty in various teaching initiatives in Switzerland.